Taysha Gene Therapies, Inc.
TSHA
$3.27
$0.113.48%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -92.72M | -86.77M | -89.30M | -22.77M | -114.34M |
| Total Depreciation and Amortization | 1.16M | 1.20M | 1.25M | 1.31M | 1.34M |
| Total Amortization of Deferred Charges | -- | -- | -- | 867.00K | 867.00K |
| Total Other Non-Cash Items | 20.25M | 19.44M | 19.30M | -43.72M | 52.96M |
| Change in Net Operating Assets | -10.81M | -17.32M | -12.47M | -14.71M | -16.20M |
| Cash from Operations | -82.13M | -83.45M | -81.23M | -79.03M | -75.37M |
| Capital Expenditure | -413.00K | -612.00K | -374.00K | -393.00K | -358.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 82.00K | 18.00K | 11.00K | 7.00K | -3.48M |
| Cash from Investing | -331.00K | -594.00K | -363.00K | -386.00K | -3.84M |
| Total Debt Issued | -- | -- | -- | 39.55M | 39.55M |
| Total Debt Repaid | -- | -- | -- | -43.00M | -43.00M |
| Issuance of Common Stock | 222.97M | 77.28M | 77.23M | 77.23M | 211.24M |
| Repurchase of Common Stock | -360.00K | -360.00K | -360.00K | -423.00K | -423.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -133.00K | -264.00K | -185.00K | -563.00K | -533.00K |
| Cash from Financing | 222.47M | 76.65M | 76.68M | 72.79M | 206.83M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.02M | -7.39M | -4.90M | -6.63M | 127.62M |